

Fang-Fang Ji
Science Editor
Editorial Office
Baishideng Publishing Group Inc.

March 29, 2017

RE: Manuscript# 31937- Potential Prognostic Biomarkers in Pancreatic Juice of Resectable Pancreatic Ductal Adenocarcinoma

Dear Dr. Ji,

We are delighted to see that our paper is of interest to the Editorial Board of the *World Journal of Clinical Oncology*. We have taken into consideration the valuable comments of the reviewers and revised the manuscript. Thank you for your considering our work for publication in your prestigious journal.

Reviewer code 02445450

We thank the reviewer for the comments. We have further clarified the potential application of CA19-9, CEA and LDH levels in pancreatic juice and bile as prognostic biomarkers in the section '*Choice of the Optimal Biomarker.*'

Reviewer code 0224612

We thank the reviewer for the comments. We have incorporated Table 1 providing a list of biomarkers of potential diagnostic and prognostic value in patients with pancreatic adenocarcinoma.

Reviewer code 00183279

We thank the reviewer for the comments. Levels of biomarkers in body fluids varies with the method of collection and laboratory protocol rendering it difficult to provide a cut-off value outside of a clinical protocol. Hyperbilirubinemia influences serum CA19-9 level however, its correlation with pancreatic juice and biliary levels of CA19-9 is not yet established. We have further elucidated the proposal to use levels of CA19-9, CEA and LDH in pancreatic juice and bile as potential prognostic biomarkers in the *Conclusion*.

Sincerely,

Shefali Agrawal, MD, MS, FACS
Senior Consultant
Hepato-Pancreato-Biliary Surgery
Department of Surgical Oncology
Indraprastha Apollo Hospitals
New Delhi 110076, India